HDAC9 and neoplasm: Moreover, treatment with vorinostat or CUDC‐907 consistently resulted in tumour growth inhibition in GBC organoid‐derived xenograft models, and as expected, the PI3K‐HDAC dual inhibitor CUDC‐907 displayed stronger antitumour activity than vorinostat (Figure 7D,E).